Arbour et al., 1996 - Google Patents
N-formyl-methionyl-leucyl-phenylalanine induces and modulates IL-1 and IL-6 in human PBMCArbour et al., 1996
- Document ID
- 827675574199938571
- Author
- Arbour N
- Tremblay P
- Oth D
- Publication year
- Publication venue
- Cytokine
External Links
Snippet
N-formyl-methionyl-leucyl-phenylalanine (fMLP), a bacterial derivative, induces and modulates various cellular responses linked to inflammation. In this work we evaluated the impact of fMLP stimulation on three pro-inflammatory cytokines: IL—1α, IL—1βand IL—6. We …
- 108010008211 N-Formylmethionine Leucyl-Phenylalanine 0 title abstract description 103
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Norment et al. | Role of chemokines in thymocyte development | |
| Mueller et al. | CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3 | |
| Gouwy et al. | Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines | |
| Matsumori et al. | Increased circulating cytokines in patients with myocarditis and cardiomyopathy. | |
| Wong et al. | Chemokines: attractive mediators of the immune response | |
| Hirai et al. | Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2 | |
| Infante-Duarte et al. | Microbial lipopeptides induce the production of IL-17 in Th cells | |
| Koski et al. | Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjogren's syndrome | |
| Muñoz et al. | IL-1 activates two separate signal transduction pathways in T helper type II cells. | |
| Köhidai et al. | Chemotaxis and chemotactic selection induced with cytokines (IL-8, Rantes and TNF-α) in the unicellular Tetrahymena pyriformis | |
| Goebeler et al. | Interleukin‐13 selectively induces monocyte chemoattractant protein‐1 synthesis and secretion by human endothelial cells. Involvement of IL‐4Rα and Stat6 phosphorylation | |
| Dinarello | Targeting interleukin 18 with interleukin 18 binding protein | |
| Heilig et al. | Evaluation of soluble tumor necrosis factor (TNF) receptors and TNF receptor antibodies in patients with systemic lupus erythematodes, progressive systemic sclerosis, and mixed connective tissue disease | |
| Lorton et al. | Chemotactic-like receptors and Aβ peptide induced responses in Alzheimer’s disease | |
| Khan et al. | Small molecule CXCR4 chemokine receptor antagonists: developing drug candidates | |
| Rosenbaum et al. | Antibodies to Beta‐Adrenergic Receptors Disclosing Agonist‐Like Properties in Idiopathic Dilated Cardiomyopathy and Chagas’ Heart Disease | |
| US20060063256A1 (en) | Human regulatory T cells and uses thereof | |
| Arbour et al. | N-formyl-methionyl-leucyl-phenylalanine induces and modulates IL-1 and IL-6 in human PBMC | |
| Guo et al. | Substance P up-regulates macrophage inflammatory protein-1β expression in human T lymphocytes | |
| US20100190710A1 (en) | Il-23 receptor antagonists and uses thereof | |
| WO2004053057A2 (en) | Gene expression systems and recombinant cell lines | |
| Eglite et al. | Requirements for C5a receptor-mediated IL-4 and IL-13 production and leukotriene C4 generation in human basophils | |
| Locati et al. | Chemokines and their receptors: roles in specific clinical conditions and measurement in the clinical laboratory | |
| Higgins et al. | N-terminus urea-substituted chemotactic peptides: new potent agonists and antagonists toward the neutrophil fMLF receptor | |
| Gavériaux-Ruff et al. | Immunosuppression by δ-opioid antagonist naltrindole: δ-and triple μ/δ/κ-opioid receptor knockout mice reveal a nonopioid activity |